VTIP evaluates, protects, and markets inventions created by researchers at Virginia Tech.
View some of the cutting edge technologies being created by researchers at Virginia Tech.

Latest News

Technology Search Results

You searched for all technologies in the category Pharmaceuticals & Biotechnology.
Your search returned 19 results.

Displaying results 1–5 of 19.
Page 1 of 4

Inhibition of Proteases Using N-terminal Peptidic Boronic Acids

VTIP:10-013

Efforts under the direction of Dr. Webster Santos have, for the first time, demonstrated the potential of using N-terminal peptidic boronic acids as protease inhibitors, specifically for ClpXP, found in the human mitochondria matrix.

Development of selective inhibitors may provide research tools for investigating physiological functions of mitochondrial proteases.

Mixed Diboron Reagents for Synthesis of Intermediates or Drugs

VTIP:10-004

The method describes the synthesis of mixed diboron reagents and their reactivity with various substrates. The method allows for the installation of a differentially protected boron onto the substrate; the orthogonal protection of boron allows the synthesis of complex molecular skeletons as synthetic intermediates or as drugs.

Filamentous Fungi Gene Required for Oxidative Stress Homeostasis and Pathogenicity and a Novel Drug Target

VTIP:09-087

The technology is a fungal specific gene that is required for both pathogenesis of plants and animals. This gene is a novel, fungal specific drug target for a new class of antifungal drugs for mammalian therapeutics and novel fungicides for agricultural applications.

An Efficient Method for Computing All Genome Subsets which Share Common Oligonucleotide Sequences of a Fixed Length

VTIP:07-076

When selecting DNA subsequences to deal with a collection of organisms with known DNA sequences many techniques have been devised to select subsequences that are common to some of the organisms. There does not appear to be any well-known method to list all possible DNA subsequences of a fixed ...

Targeted Compounds for Prostate Cancer Treatment

VTIP:07-058

Available for licensing are novel chemical compounds which are bifunctional and bind to the androgen receptor (AR), a ligand-dependent transcription factor. These compounds comprise tubulin-binding and steroid receptor-binding moieties. They are designed to antagonize AR function in a nonclassical manner by several mechanisms and kill hormone-refractory prostate cells better than ...

Page 1 of 4